contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bulletin-from-the-extraordinary-general-meeting-of-lipidor-ab-publ-2

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Lipidor is a pharmaceutical company. The company works with research and development in the preclinical and clinical phases. The largest business is established in the development of pharmaceuticals that are further used for the treatment of various skin diseases. Examples of diseases that are treated include psoriasis, various skin infections, and atopic dermatitis. The head office is located in Solna. 

Lipidor

The following resolutions were passed at the Extraordinary General Meeting (the “EGM”) of Lipidor AB (publ) (the “Company”) on 21 May 2024 in Stockholm.Rights issue of units The EGM resolved...

<div class="mfn-preamble"><p><strong>The following resolutions were passed at the Extraordinary General Meeting (the “EGM”) of Lipidor AB (publ) (the “Company”) on 21 May 2024 in Stockholm.</strong></p></div><div class="mfn-body"><p><strong>Rights issue of units</strong><br>The EGM resolved to approve the Board of Directors’ resolution on a new issue of units, consisting of shares and warrants of series TO 2, with pre-emption rights for the shareholders, as announced by the Company in press release on 10 April 2024 (the “<strong>Rights Issue</strong>”).</p><p>For detailed information on the terms for the Rights Issue and the resolution adopted at this EGM please see the notice that is available on the Company’s website, <a rel="noopener" href="http://www.lipidor.se/">www.lipidor.se</a>.</p><p>Complete terms and conditions for the Rights Issue and other information about the Company will be set out in the EU Growth prospectus prepared in connection with the Rights Issue, which is expected to be published on or around 24 May 2024.</p><p><strong>Amendments of the Articles of Association</strong><br>The EGM resolved, in accordance with the Board’s proposal, to adopt new Articles of Association. The new Articles of Association contain amended limits for the share capital and the number of shares to enable the Rights Issue. Furthermore, the new Articles of Association contain a provision allowing the General Meeting to be held digitally.</p></div><div class="mfn-footer mfn-contacts mfn-ec2f69be0eda"><p><strong class="mfn-heading-1">For more information, please contact:</strong></p><p>Ola Holmlund, CEO<br>Telephone: +46 (0) 72 50 70 369<br>Email: <a rel="noopener" href="mailto:ola.holmlund@lipidor.se">ola.holmlund@lipidor.se</a></p><p>The company’s Certified Adviser is Carnegie Investment Bank AB (publ).</p></div><div class="mfn-footer mfn-about mfn-e061b566de55"><p><strong class="mfn-heading-1">About Lipidor AB</strong><br>Lipidor AB (Nasdaq First North Growth Market: LIPI) (<a rel="noopener" href="http://www.lipidor.se">www.lipidor.se</a>) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of&nbsp;proven&nbsp;pharmaceutical substances. Lipidor’s priority project is AKP02G2, which focusses on psoriasis.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/ccdf3b6a-a2a7-4489-8800-253dc28a3279/bulletin-from-the-extraordinary-general-meeting-of-lipidor-ab-publ.pdf" class="mfn-generated mfn-primary">Bulletin from the Extraordinary General Meeting of Lipidor AB (publ)</a></p></div>

Bulletin from the Extraordinary General Meeting of Lipidor AB (publ)

Federal Reserven korkopäätös: Kiire loppui tähän

Drug development investment: Value creation through M&As and licensing agreements

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

Laskuviikko takana Euroopassa, EKP:n viesti sai lopulta velkakirjakorot nousuun

Stay up to date with our newsletter